EverSource Wealth Advisors LLC Raises Stake in Becton, Dickinson and Company (NYSE:BDX)

EverSource Wealth Advisors LLC boosted its position in Becton, Dickinson and Company (NYSE:BDXGet Rating) by 70.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 254 shares of the medical instruments supplier’s stock after buying an additional 105 shares during the period. EverSource Wealth Advisors LLC’s holdings in Becton, Dickinson and were worth $68,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of BDX. Somerset Trust Co lifted its holdings in Becton, Dickinson and by 0.3% in the first quarter. Somerset Trust Co now owns 14,459 shares of the medical instruments supplier’s stock valued at $3,846,000 after acquiring an additional 39 shares during the period. First Citizens Bank & Trust Co. lifted its holdings in Becton, Dickinson and by 4.1% in the fourth quarter. First Citizens Bank & Trust Co. now owns 1,016 shares of the medical instruments supplier’s stock valued at $255,000 after acquiring an additional 40 shares during the period. Blossom Wealth Management raised its stake in shares of Becton, Dickinson and by 3.5% during the 1st quarter. Blossom Wealth Management now owns 1,192 shares of the medical instruments supplier’s stock worth $317,000 after buying an additional 40 shares during the period. Mitchell Mcleod Pugh & Williams Inc. raised its stake in shares of Becton, Dickinson and by 1.1% during the 1st quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 3,805 shares of the medical instruments supplier’s stock worth $1,012,000 after buying an additional 40 shares during the period. Finally, Dorsey & Whitney Trust CO LLC raised its stake in shares of Becton, Dickinson and by 1.6% during the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 2,535 shares of the medical instruments supplier’s stock worth $675,000 after buying an additional 41 shares during the period. Hedge funds and other institutional investors own 86.74% of the company’s stock.

Becton, Dickinson and Stock Down 0.9 %

Shares of NYSE:BDX opened at $254.32 on Friday. The stock has a market cap of $72.53 billion, a P/E ratio of 43.85, a PEG ratio of 3.36 and a beta of 0.57. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.58. Becton, Dickinson and Company has a 52-week low of $231.46 and a 52-week high of $280.62. The business has a fifty day moving average of $251.96 and a two-hundred day moving average of $254.81.

Becton, Dickinson and (NYSE:BDXGet Rating) last released its quarterly earnings results on Thursday, August 4th. The medical instruments supplier reported $2.66 earnings per share for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. The business had revenue of $4.64 billion during the quarter, compared to analysts’ expectations of $4.47 billion. Becton, Dickinson and had a return on equity of 14.55% and a net margin of 8.88%. The company’s revenue was down 5.1% compared to the same quarter last year. During the same period in the prior year, the business posted $2.74 EPS. On average, research analysts expect that Becton, Dickinson and Company will post 11.31 earnings per share for the current year.

Becton, Dickinson and Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 30th. Stockholders of record on Friday, September 9th will be issued a dividend of $0.87 per share. This represents a $3.48 dividend on an annualized basis and a dividend yield of 1.37%. The ex-dividend date is Thursday, September 8th. Becton, Dickinson and’s dividend payout ratio is presently 60.00%.

Insider Buying and Selling

In related news, CEO Thomas E. Polen, Jr. sold 9,500 shares of the stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $265.13, for a total transaction of $2,518,735.00. Following the transaction, the chief executive officer now owns 28,878 shares of the company’s stock, valued at approximately $7,656,424.14. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Becton, Dickinson and news, EVP Samrat S. Khichi sold 9,185 shares of the stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $260.44, for a total value of $2,392,141.40. Following the sale, the executive vice president now owns 5,928 shares of the company’s stock, valued at approximately $1,543,888.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Thomas E. Polen, Jr. sold 9,500 shares of the stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $265.13, for a total value of $2,518,735.00. Following the completion of the sale, the chief executive officer now directly owns 28,878 shares in the company, valued at approximately $7,656,424.14. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 19,160 shares of company stock valued at $5,036,751. Corporate insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

BDX has been the subject of several research analyst reports. Wells Fargo & Company raised Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $275.00 target price for the company in a research note on Friday, June 24th. The Goldman Sachs Group upped their target price on Becton, Dickinson and from $278.00 to $319.00 and gave the stock a “buy” rating in a research note on Tuesday, August 16th. Morgan Stanley reduced their target price on Becton, Dickinson and from $282.00 to $272.00 and set an “overweight” rating for the company in a research note on Friday, July 15th. StockNews.com raised Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Saturday, September 10th. Finally, Citigroup downgraded Becton, Dickinson and from a “neutral” rating to a “sell” rating and reduced their price objective for the company from $265.00 to $235.00 in a research note on Monday, July 11th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $277.63.

Becton, Dickinson and Profile

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Recommended Stories

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXGet Rating).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.